Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Sykes Enterprises Turns To Q4 Profit, Provides Q1, FY12 Outlook

RELATED NEWS
Trade SYKE now with 
2/27/2012 4:41 PM ET

Sykes Enterprises, Inc. (SYKE: Quote) Monday reported fourth-quarter net income of $5.1 million or $0.12 per share, compared to a net loss of $17.0 million or $0.37 per share in the year-ago quarter.

Results for the quarter include a $0.02 per share loss from discontinued operations, compared with a loss of $0.61 per share in the year-ago quarter.

Earnings per share from continuing operations were $0.14 versus $0.24 in the comparable quarter last year.

On an adjusted basis, earnings per share from continuing operations were $0.27 versus $0.35 in the same period last year, with the decline attributed primarily to a combination of unfavorable foreign currency movements and a higher effective tax rate.

On average, 9 analysts polled by Thomson Reuters expected earnings of $0.28 per share for the quarter. Analysts' estimates typically exclude special items.

Results for the quarter reflect the exclusion of revenues and expenses from the operations in Spain.

Revenues from continuing operations decreased 8.1 percent to $276.2 million from $300.4 million in the year-ago quarter. On a constant currency basis, revenues from continuing operations decreased 6.8 percent. Seven Street analysts had a consensus revenue estimate of $287.7 million.

The company said healthy demand within the financial services vertical was more than offset by a combination of certain previously discussed end-of-life client programs and muted demand.

Going forward, the company remains cautious but is, however, encouraged by the sales pipeline activity and conversion rates from certain existing and new clients within the Americas and EMEA regions.

The company plans to add approximately 3,700 seats on a gross basis in 2012. The company believes 2012-2011 quarterly revenue comparisons should turn favorable in the fourth quarter of 2012.

For the first quarter, the company expects earnings per share of about $0.12 to $0.15, adjusted earnings per share in the range of $0.20 to $0.23, and revenues in the range of $270.0 million to $275.0 million. Street expect earnings of $0.30 per share on revenues of $300.7 million.

For the full year ending December 31, 2012, the company expects earnings per share of about $0.88 to $0.98, adjusted earnings per share in the range of $1.10 to $1.20, and revenues in the range of $1.095.0 billion to $1.110.0 billion. Analysts currently expect earnings of $1.44 per share on revenues of $1.22 billion.

Register
To receive FREE breaking news email alerts for Sykes Enterprises Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Gap Inc. Thursday after the markets closed that its first quarter profit rose 43% from last year, helped by higher sales and improved margins. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company eaffirmed its fiscal year 2013 earnings outlook, which is below analysts' current consensus estimate. After moving sharply lower at the start of trading on Thursday, stocks showed a substantial recovery attempt over the course of the trading day. The rebound came as upbeat housing data helped offset worries about the Federal Reserve. The major averages climbed well off their worst levels of the day but still ended the session in the red. President Barack Obama delivered a highly-anticipated speech on his administration's evolving counterterrorism policies on Thursday, suggesting that the U.S. needs to move away from a "boundless global war on terror." More than a decade after the 9/11 attacks, Obama argued that the terrorist threat has shifted and evolved.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.